Adaptive Biotechnologies ADPT Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 74.2%+14.5pp | 59.7%+4.1pp | 55.6%-13.1pp | 68.7%+0.7pp | |
| Operating margin | -20.6%+70.2pp | -90.8%+42.5pp | -133.3%-25.3pp | -108%+27.4pp | |
| Net margin | -21.5%+67.6pp | -89.1%+43.2pp | -132.3%-24.3pp | -108%+26.3pp | |
| EBITDA margin | -14.2%+65.9pp | -80.1%+40.2pp | -120.3%-23.5pp | -96.7%+29.6pp | |
| Free cash flow margin | -18.2%+37.1pp | -55.3%+42.8pp | -98.1%+10.0pp | -108.1%+56.8pp | |
| Returns | |||||
| Return on equity | -28.2%+34.2pp | -62.4%-4.1pp | -58.3%-20.8pp | -37.5%-6.7pp | |
| Return on assets | -11.3%+15.3pp | -26.6%+3.1pp | -29.7%-7.2pp | -22.5%-2.2pp | |
| Return on invested capital | -15.5%+22.7pp | -38.2%+3.8pp | -42%-8.2pp | -33.8%-1.8pp | |
| Efficiency | |||||
| Asset turnover | 0.5×+0.2× | 0.3×+0.1× | 0.2×0.0× | 0.2×+0.1× | |
| Inventory turnover | 7.8×+1.5× | 6.3×+1.1× | 5.2×+1.8× | 3.4×+0.5× | |
| Liquidity | |||||
| Current ratio | 3.3×+0.4× | 2.9×-1.8× | 4.7×-0.5× | 5.1×+1.6× | |
| Quick ratio | 3.2×+0.4× | 2.8×-1.7× | 4.5×-0.5× | 5×+1.6× | |
| Cash ratio | 0.8×+0.3× | 0.5×-0.3× | 0.7×-0.1× | 0.8×-0.4× | |
| Leverage | |||||
| Debt-to-equity | 1×-0.1× | 1.1×+0.4× | 0.7×+0.2× | 0.5×+0.3× | |
| Debt-to-assets | 0.4×0.0× | 0.4×+0.1× | 0.3×+0.1× | 0.3×+0.2× | |
| Interest coverage | -4.9×+9.2× | -14×+2.4× | -16.5×— | —— | |
| Per Share | |||||
| Book value per share | $1.44+4.7% | $1.38-35.5% | $2.14-34.4% | $3.26-24.3% | |
| Valuation | |||||
| Market capitalization | $2.48B+180% | $884.74M+24.7% | $709.39M-35.1% | $1.09B-72.4% | |
| Enterprise value | $2.62B+147% | $1.06B+21.3% | $873.75M-29.3% | $1.24B-68.6% | |
| Price / sales | 9×+4.0× | 4.9×+0.8× | 4.2×-1.7× | 5.9×-19.8× | |
| Price / book | 11.3×+7.0× | 4.4×+2.1× | 2.3×-0.1× | 2.4×-4.2× | |
| EV / sales | 9.5×+3.5× | 5.9×+0.8× | 5.1×-1.5× | 6.7×-18.8× | |
| Free cash flow yield | -2%+9.1pp | -11.2%+12.4pp | -23.5%-5.2pp | -18.3%-11.9pp | |
| Earnings yield | -2.4%+15.6pp | -18%+13.7pp | -31.8%-13.4pp | -18.3%-13.1pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Adaptive Biotechnologies's profit margins?
- Adaptive Biotechnologies (ADPT) runs a 75.3% gross margin and a -15.8% operating margin, with a -16.8% net margin.
- Where do Adaptive Biotechnologies's ratios come from?
- Every ratio is computed from Adaptive Biotechnologies's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
